IDEAYA Biosciences, Inc. (IDYA)
| Market Cap | 922.30M |
| Revenue (ttm) | 26.79M |
| Net Income (ttm) | -31.47M |
| Shares Out | 31.76M |
| EPS (ttm) | -1.14 |
| PE Ratio | n/a |
| Forward PE | 4.65 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 28 |
| Last Price | $23.93 |
| Previous Close | $22.72 |
| Change ($) | 1.21 |
| Change (%) | 5.33% |
| Day's Open | 22.83 |
| Day's Range | 22.40 - 24.20 |
| Day's Volume | 89,940 |
| 52-Week Range | 10.90 - 26.00 |
SOUTH SAN FRANCISCO, Calif., July 12, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the closing of its underwritten public offering of 5,333,333 shares of its common stock ...
SOUTH SAN FRANCISCO, Calif., July 7, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the pricing of an underwritten public offering of 4,637,681 shares of its common stock at...
Ideaya Biosciences Inc (NASDAQ: IDYA) has offered up to $80 million shares in an underwritten public offering. Underwriters have an option to purchase up to $12 million of shares.
SOUTH SAN FRANCISCO, Calif., July 6, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced that it intends to offer and sell up to $80 million of shares of its common stock in an u...
SOUTH SAN FRANCISCO, Calif., June 28, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and develo...
SOUTH SAN FRANCISCO, Calif., May 24, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and develo...
IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of 0.00% and -27.31%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
SOUTH SAN FRANCISCO, Calif., May 10, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and develop...
SOUTH SAN FRANCISCO, Calif., May 10, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and develo...
SOUTH SAN FRANCISCO, Calif., May 6, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and develop...
SOUTH SAN FRANCISCO, Calif., April 19, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and deve...
SOUTH SAN FRANCISCO, Calif., April 16, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and deve...
SOUTH SAN FRANCISCO, Calif., April 15, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and deve...
SOUTH SAN FRANCISCO, Calif., April 15, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and deve...
IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of 0.00% and -2.84%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
SOUTH SAN FRANCISCO, Calif., March 23, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and deve...
SOUTH SAN FRANCISCO, Calif., March 23, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and devel...
SOUTH SAN FRANCISCO, Calif., March 11, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and deve...
SOUTH SAN FRANCISCO, Calif., March 1, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and devel...
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2021 /PRNewswire/ --IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and develo...
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and devel...
SOUTH SAN FRANCISCO, Calif., Feb. 8, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and develo...
SOUTH SAN FRANCISCO, Calif., Feb. 1, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted t...
SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted t...
SOUTH SAN FRANCISCO, Calif., Jan. 5, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted th...
SOUTH SAN FRANCISCO, Calif., Jan. 4, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted th...
SOUTH SAN FRANCISCO, Calif., Dec. 14, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted ...
IDEAYA Biosciences (IDYA) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted ...
SOUTH SAN FRANCISCO, Calif., Nov. 2, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted th...
SOUTH SAN FRANCISCO, Calif., Oct. 22, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted ...
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted...
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc.
IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of -126.34% and -100.00%, respectively, for the quarter ended June 2020.
SOUTH SAN FRANCISCO, Calif., Aug. 12, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc.
IDEAYA Biosciences (IDYA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
SOUTH SAN FRANCISCO, Calif., Aug. 4, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., July 16, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., July 14, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted ...
SOUTH SAN FRANCISCO, Calif., July 9, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted th...
SOUTH SAN FRANCISCO, Calif., June 30, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted t...
A high-profile partnership and a promising pipeline of oncology-focused treatments suggest favorable reward-versus-risk in IDYA stock. The post Target Breakthrough Science and Medicine with Ideaya Biosc...
Here's what pushed up shares of the highest-flying healthcare stocks.
The development-stage drug developer is selling common stock to raise cash. It's a wise move.
SOUTH SAN FRANCISCO, Calif., June 17, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced the pricing of an underwritten public offering of 6,666,667 shares of its common stock ...
SOUTH SAN FRANCISCO, Calif., June 16, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced that it intends to offer and sell up to $60 million of shares of its common stock in an ...
IDEAYA Biosciences (NASDAQ: IDYA) shares are trading higher on Tuesday, after the company, along with GSK, announced a partnership in Synthetic Lethality.
SOUTH SAN FRANCISCO, Calif. and LONDON, June 16, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA) and GlaxoSmithKline plc (GSK) announce a strategic partnership in Synthetic Lethality, an em...
SOUTH SAN FRANCISCO, Calif., June 11, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) is an oncology-focused precision medicine company committed to the discovery and development of targeted...
IDEAYA (IDYA) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
About IDYA
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate is IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting IDE397, a methionine adenosyltransferase 2a inhibitor for patients wit... [Read more...]
| Industry Biotechnology | IPO Date May 23, 2019 |
| CEO Yujiro Hata | Employees 69 |
| Stock Exchange NASDAQ | Ticker Symbol IDYA |
Analyst Forecasts
According to 9 analysts, the average rating for IDYA stock is "Strong Buy." The 12-month stock price forecast is 31.56, which is an increase of 31.88% from the latest price.